Clinical Trial Update: Mitochondrial Oxidation and Insulin Resistance in Burn Patients Treated With Fenofibrate [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 clinical trial evaluating fenofibrate for mitochondrial oxidation and insulin resistance in burn patients has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Burn Injury

Drugs mentioned

• FENOFIBRATE (Fenofibrate)

Snippet

Sponsor: The University of Texas Medical Branch, Galveston | Conditions: Burn | Phase 2, Phase 3 | Status: WITHDRAWN